BGBrooke N. Gleason

Brooke N. Gleason

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brooke N. Gleason has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Atsushi Kato

    Department of Otolaryngology–Head and Neck Surgery Northwestern University Feinberg School of Medicine Chicago Illinois USA

    4 shared publications
  • David B. Conley

    Department of Otolaryngology–Head and Neck Surgery Northwestern University Feinberg School of Medicine Chicago Illinois USA

    4 shared publications
  • Kevin C. Welch

    Department of Otolaryngology–Head and Neck Surgery Northwestern University Feinberg School of Medicine Chicago Illinois USA

    4 shared publications
  • Robert C. Kern

    Department of Otolaryngology–Head and Neck Surgery Northwestern University Feinberg School of Medicine Chicago Illinois USA

    4 shared publications
  • Bruce K. Tan

    Department of Otolaryngology Northwestern University Feinberg School of Medicine Chicago Illinois USA

    3 shared publications
  • Stephanie Shintani Smith

    Department of Otolaryngology Northwestern University Feinberg School of Medicine Chicago Illinois USA

    3 shared publications

Latest Publications

  • Biomarker Axes, Detection Limits, and Endotype Stability in CRS: Reply to Katkuri et al. and Hong

    by Asher C. Park, Brooke N. Gleason, Eli Stein, Saied Ghadersohi, Atsushi Kato, Stephanie Shintani‐Smith, David B. Conley, Kevin C. Welch, Robert C. Kern, Bruce K. Tan

  • Open Access

    Appropriate Medical Therapy Primarily Modifies Type 2 and Severity Biomarkers in Chronic Rhinosinusitis

    by Asher C. Park, Brooke N. Gleason, Eli Stein, Saied Ghadersohi, Atsushi Kato, Stephanie Shintani‐Smith, David B. Conley, Kevin C. Welch, Robert C. Kern, Bruce K. Tan

    Background: Appropriate medical therapy (AMT) is first‐line treatment for patients with chronic rhinosinusitis (CRS). We evaluated inflammatory structure, treatment‐induced changes, and biomarker‐outcome associations in AMT‐managed patients. Methods: Fifty‐one CRS patients were evaluated before and after AMT which included a combination of oral antibiotics, oral steroids, or intranasal steroids tailored to CRS phenotype and severity. At each visit, patients completed the SNOT‐22, CRS‐PRO, Brief Smell Identification Test (BSIT), CT scan (Lund–Mackay Score [LM]), and endoscopy (Modified Lund–Kennedy Score [MLK]). Middle‐meatal mucus was analyzed for IL‐1b, IL‐5, IL‐13, IFN‐g, and MIP1a using Luminex and ELISA. Principal components analysis (PCA) was performed on baseline cytokine data to identify key biomarker axes. Paired‐sample Wilcoxon tests compared cytokine changes, and Spearman's correlation assessed relationships between biomarkers and disease measures. Results: PCA revealed two major components: PC‐1 (inflammation severity) dominated by ECP and MIP1a, and PC‐2 (endotype axis) with positive weighting of IL‐5 and IL‐13 (T2) and negative weighting of IFN‐g and IL‐1b (T1/3). AMT significantly reduced inflammatory severity and T2 biomarker burden, driven by decreases in IL‐5, IL‐13, ECP, and MIP1a (all p < 0.01), while T1/3 biomarker remained unchanged. Clinical outcomes, including MLK, SNOT‐22, CRS‐PRO, and BSIT, improved and showed stronger correlations with T2 than T1/3 biomarkers. Conclusion: AMT for CRS is associated with reduction in index biomarkers across inflammatory severity and T2 endotype with minimal effects on T1/3 inflammation. T2‐driven inflammation appears to be the most AMT‐responsive axis found in this study, aligning with measurable improvements in endoscopic, patient reported, and nasal airflow outcomes.


  • Open Access

    Effect and Threshold of Endoscopic Findings for CRS Control Status and Long‐Term Outcome Prediction

    by Steven Chun‐Kang Liao, Aditi Agarwal, Junqin Bai, Zhidi Luo, Siyuan Dong, Regan L. Harmon, Brooke N. Gleason, Julia Huang, David B. Conley, Kevin C. Welch, et al.

    Background: EPOS 2020 defined chronic rhinosinusitis (CRS) disease control using patient symptoms and medication usage but endoscopic findings were considered optional. The effect of adding endoscopic features, an appropriate threshold, and their association with present or future symptom control have not been studied. Methods: A prospective cohort study of 188 adult CRS patients undergoing bilateral endoscopic sinus surgery from 2017 to 2023 was conducted. Patients were assessed at 6–12 months (V1) and 18–60 months (V2) postoperatively. Individual patient symptoms from the SNOT‐22, endoscopic findings (modified Lund–Kennedy [MLK] score), and medication usage were recorded. CRS control status was classified as controlled or suboptimal control (EPOS partly/un‐controlled) based on EPOS 2020 criteria without endoscopic features. The predictive role of endoscopic findings was analyzed. Results: Endoscopic findings were weakly associated with concurrent control status but the total MLK (V1 AUC = 0.631, p < 0.001; V2 AUC = 0.620, p < 0.05) outperformed any individual MLK component in strength of association. Adding MLK to V1 control status using a threshold of MLK ≥ 3 marginally improved prediction accuracy for V2 control compared to V1 control status defined without endoscopic features (AUC = 0.744 vs. 0.721, respectively, both p < 0.001). Conclusion: While endoscopic findings are only weakly associated with concurrent control status, their addition enhances prediction of subsequent V2 CRS outcomes. Our study provides the first real‐world evidence supporting the value of endoscopic findings as predictors for CRS disease progression, with an MLK threshold ≥ 3 showing moderate predictive accuracy for future maintenance of control.

  • Open Access

    Factor Analysis‐Based Quantitative Endotyping Improves Associations With CRS Cross‐Sectional and Longitudinal Outcomes

    by Brooke N. Gleason, Zhidi Luo, Aditi Agarwal, Siyuan Dong, Regan L. Harmon, Junqin Bai, Chun‐Kang Liao, Julia Huang, David B. Conley, Kevin C. Welch, et al.

    Background: Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease characterized by persistent sinonasal inflammation. There is increasing interest in endotype‐based classification, which categorizes CRS based on underlying inflammatory pathways. We applied factor analysis to facilitate continuous endotype assignment to CRS patients and assess cross‐sectional and longitudinal CRS outcomes. Methods: We prospectively enrolled 203 patients (52 controls, 88 CRSsNP, and 63 CRSwNP) undergoing endoscopic nasal or sinus surgery (ESS). Middle meatal mucus biomarkers were analyzed pre‐ESS (V0) and 6–12 months post‐ESS (V1). Factor analysis was performed to identify latent factors. Factor scores were generated, and statistical analyses were conducted to assess correlations with radiographic (Lund–Mackay [LM]) and patient‐reported (SNOT‐22, CRS‐PRO) outcomes measured at V0, V1, and V2 (1.5–5 years post‐ESS). Results: Four factors were identified: Type 1 (T1), Type 2 (T2), Type 3 (T3), and macrophage‐associated (M). CRSwNP patients had higher T2 and M factor scores than CRSsNP and controls. T2, T3, and M factor scores demonstrated stronger or equivalent associations with radiographic and patient‐reported outcomes compared to individual biomarkers. Following ESS, median T2 and M factor scores significantly declined, while T1 and T3 remained stable. V0 T1 and T2 were weakly associated with long‐term (V2) radiographic and symptom scores. V1 factor scores were more consistently predictive of long‐term (V2) outcomes, with T2, T3, and M demonstrating modest correlations with radiographic severity and CRS‐PRO. Conclusions: Factor analysis identifies distinct, quantifiable patterns of inflammation in CRS, offering improved associations with cross‐sectional and longitudinal outcomes compared to individual biomarkers.